China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy |
| December 30, 2022 | December 2022 Bond Updates |
|
STOCKHOLM, Dec. 30, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has recommended Priority Review for the... |
| View more at: https://www.prnewswire.com:443/news-releases/china-cdenmpa-recommends-priority-review-for-nefecon-for-the-treatment-of-primary-iga-nephropathy-301711326.html |
| Related News |
|